Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02612857 · ClinicalTrials.gov registry record · Phase 2
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2 study, sponsored by Idera Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT02612857: Completed Phase 2 study, sponsored by Idera Pharmaceuticals.
NCT02612857 is a Phase 2 study that has completed, run by Idera Pharmaceuticals. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02612857, a Phase 2 study, has completed, sponsored by Idera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how safe and effective IMO-8400 is in adults with dermatomyositis.
Primary Outcome
Number of participants with different types of Treatment Emergent Adverse Events
Interventions
- DRUG Placebo
- DRUG IMO-8400 Dose Group 1
- DRUG IMO-8400 Dose Group 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-11 |
| Est. Completion | 2018-06 |
| Phase | Phase 2 |
What the finished NCT02612857 record still lists
NCT02612857 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02612857 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02612857 about?
NCT02612857 is a clinical study titled "Trial of IMO-8400 in Adult Patients With Dermatomyositis". The purpose of this study is to determine how safe and effective IMO-8400 is in adults with dermatomyositis.
What is the current status of trial NCT02612857?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2015-11. Estimated completion is 2018-06.
What interventions are being tested in trial NCT02612857?
The interventions under investigation include: Placebo (DRUG), IMO-8400 Dose Group 1 (DRUG), IMO-8400 Dose Group 2 (DRUG).
Who is sponsoring clinical trial NCT02612857?
This trial is sponsored by Idera Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02612857's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia